Omicia

We help researchers and clinicians understand, interpret, and report on DNA sequencing data

Opal™, Omicia’s comprehensive genome interpretation platform, significantly improves the accuracy, speed, and cost of translating DNA sequencing data into actionable information.

Opal is designed for:

  • Disease research
  • Diagnostic testing and reporting
  • Clinical trials management and drug development

Schedule a free demo and learn how Opal can work for you

A primer on genome interpretation:
How Omicia is transforming personalized medicine


Opal Genome Interpretation Platform

Next-generation genome interpretation and reporting software

  • Annotate genomes and exomes
  • Identify disease-causing gene variants
Learn more about Opal Research >>
  • Develop NGS disease gene panels & diagnostic tests
  • Generate customizable clinical reports
Learn More about Opal Clinical >>
  • Identify genomic biomarkers
  • Design more intelligent clinical trials
Learn more about Opal Clinical Trials >>

Our Customers

Omicia continues to lead the genome analysis field by partnering with world-renowned institutions. Their invaluable contributions and feedback keep Omicia at the forefront of clinical genome interpretation.

aruplabs
cornell
ecolepoly
uofvienna
uofutah
uofmiami
ucsc
osaka
mahidol
mountsinai
kiel
johnhopkins
ucsf
craig-venter
ngi
coldspring

Recent News


September 17, 2014
Omicia feautured in Nature article, “When Disease Strikes from Nowhere.” How new software tools help identify disease-causing mutations

Read More

June 3, 2014
Omicia and LabCorp collaborate to offer comprehensive genomic analysis services for next-generation clinical trials

Read more

March 18, 2014
Omicia co-founder & president, Martin Reese, speaks to Mendelspod about scaling up clinical interpretation of the human genome

Watch the interview